Overview

Phase 2, Multiple Ascending Dose Proof of Concept Study

Status:
Completed
Trial end date:
2017-07-18
Target enrollment:
Participant gender:
Summary
This is a phase 2a study to evaluate the safety and tolerability of multiple oral doses of CMX157 at increasing dose levels.
Phase:
Phase 2
Details
Lead Sponsor:
ContraVir Pharmaceuticals, Inc.
Treatments:
Hexadecyloxypropyl 9-(2-(phosphonomethoxy)propyl)adenine
Tenofovir